Format

Send to

Choose Destination
Vaccine. 2009 Aug 27;27(39):5299-306. doi: 10.1016/j.vaccine.2009.06.101. Epub 2009 Jul 17.

Epitope-based vaccination against pneumonic tularemia.

Author information

1
Rhode Island Hospital and The Warren Alpert Medical School of Brown University, Providence, RI, United States. sgregory@lifespan.org

Abstract

Francisella tularensis, the etiological agent of tularemia, is one of the most infectious bacterial pathogens known. No vaccine is currently approved for public use. Previously, we identified epitopes recognized specifically by T cells obtained from individuals following infection with F. tularensis. Here, we report that a subunit vaccine constructed based upon these epitopes elicited protective immunity in "humanized" HLA class II (DRB1*0401) transgenic mice. Vaccinated mice challenged intratracheally with a lethal dose of F. tularensis (Live Vaccine Strain) exhibited a rapid increase in pro-inflammatory cytokine production and diminished number of organisms in the lungs, and a concurrent increased rate of survival. These results demonstrate the efficacy of an epitope-based tularemia vaccine and suggest that such an approach might be widely applicable to the development of vaccines specific for intracellular bacterial pathogens.

PMID:
19616492
PMCID:
PMC2772204
DOI:
10.1016/j.vaccine.2009.06.101
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center